SE446336B - SET TO MAKE A 1.5-DISUBSTITUTED HYDANTOIN WHICH HAS INHIBITIVE EFFECT ON BLOOD SPOT SEGREGATION - Google Patents

SET TO MAKE A 1.5-DISUBSTITUTED HYDANTOIN WHICH HAS INHIBITIVE EFFECT ON BLOOD SPOT SEGREGATION

Info

Publication number
SE446336B
SE446336B SE7706428A SE7706428A SE446336B SE 446336 B SE446336 B SE 446336B SE 7706428 A SE7706428 A SE 7706428A SE 7706428 A SE7706428 A SE 7706428A SE 446336 B SE446336 B SE 446336B
Authority
SE
Sweden
Prior art keywords
make
blood spot
inhibitive effect
disubstituted hydantoin
spot segregation
Prior art date
Application number
SE7706428A
Other languages
Swedish (sv)
Other versions
SE7706428L (en
Inventor
A G Caldwell
N Whittaker
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE7706428L publication Critical patent/SE7706428L/en
Publication of SE446336B publication Critical patent/SE446336B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
SE7706428A 1976-06-03 1977-06-02 SET TO MAKE A 1.5-DISUBSTITUTED HYDANTOIN WHICH HAS INHIBITIVE EFFECT ON BLOOD SPOT SEGREGATION SE446336B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2287776 1976-06-03
GB5034076 1976-12-02
GB1214577 1977-03-23

Publications (2)

Publication Number Publication Date
SE7706428L SE7706428L (en) 1977-12-04
SE446336B true SE446336B (en) 1986-09-01

Family

ID=27256793

Family Applications (2)

Application Number Title Priority Date Filing Date
SE7706428A SE446336B (en) 1976-06-03 1977-06-02 SET TO MAKE A 1.5-DISUBSTITUTED HYDANTOIN WHICH HAS INHIBITIVE EFFECT ON BLOOD SPOT SEGREGATION
SE8203161A SE8203161L (en) 1976-06-03 1982-05-19 SET TO MAKE 1,5-DISUBSTITUTED HYDANTOIN ANALOGS

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE8203161A SE8203161L (en) 1976-06-03 1982-05-19 SET TO MAKE 1,5-DISUBSTITUTED HYDANTOIN ANALOGS

Country Status (12)

Country Link
JP (1) JPS52151168A (en)
CA (1) CA1176261A (en)
CH (3) CH645631A5 (en)
DE (1) DE2724948A1 (en)
DK (1) DK244577A (en)
ES (5) ES459412A1 (en)
FI (1) FI71930C (en)
FR (1) FR2362839A1 (en)
HU (1) HU183046B (en)
NL (1) NL7706064A (en)
NZ (1) NZ184281A (en)
SE (2) SE446336B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1602188A (en) * 1977-12-01 1981-11-11 Wellcome Found Hydantoin derivatives
EP0001238B1 (en) * 1977-09-05 1984-07-04 The Wellcome Foundation Limited Hydantoin derivatives, their synthesis, pharmaceutical formulations and intermediates in their preparation
JPS5492962A (en) * 1977-12-01 1979-07-23 Wellcome Found Thiohydantoin compound
EP0003410B1 (en) * 1978-01-23 1982-10-06 Beecham Group Plc Hydantoins and thiohydantoins, method for their preparation and pharmaceutical compositions containing them
EP0004723A1 (en) * 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
GB1599740A (en) * 1978-05-31 1981-10-07 Wellcome Found Hydantoin derivatives
EP0007180B1 (en) * 1978-06-15 1983-03-30 Beecham Group Plc Prostaglandin analogue triazole derivatives, processes for their preparation and a pharmaceutical composition containing them
AU4778279A (en) * 1978-06-15 1979-12-20 Beecham Group Limited Prostaglandin analogues
IL57504A0 (en) * 1978-06-15 1979-10-31 Beecham Group Ltd Prostagandin analogues,their preparation and pharmaceutical compositions containing
EP0006352A1 (en) * 1978-06-15 1980-01-09 Beecham Group Plc Hydantoins and thiohydantoins, process for their preparation and pharmaceutical compositions containing them
IL59065A0 (en) 1979-01-18 1980-05-30 Beecham Group Ltd Hydantoin derivatives,their preparation pharmaceutical compositons containing them
GB2050371A (en) * 1979-05-09 1981-01-07 Wellcome Found Optically active hydantoin derivatives and pharmaceutical formulations containing them
US4684735A (en) * 1985-07-01 1987-08-04 Stauffer Chemical Company Promotion of raney nickel hydrogenation catalyst
JP3022878U (en) * 1995-08-18 1996-04-02 有限会社春江加工 Case for mini discs
EP1453811A2 (en) * 2001-11-30 2004-09-08 Eli Lilly And Company Peroxisome proliferator activated receptor agonists
CA2528179C (en) * 2003-06-06 2013-10-22 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) * 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins

Also Published As

Publication number Publication date
NL7706064A (en) 1977-12-06
DE2724948A1 (en) 1977-12-15
JPS6222986B2 (en) 1987-05-20
NZ184281A (en) 1980-04-28
FI71930B (en) 1986-11-28
ES8103057A1 (en) 1981-02-16
FR2362839B1 (en) 1980-02-01
FR2362839A1 (en) 1978-03-24
DK244577A (en) 1977-12-04
CA1176261A (en) 1984-10-16
ES470428A1 (en) 1979-09-01
ES459412A1 (en) 1978-11-01
CH645631A5 (en) 1984-10-15
CH647511A5 (en) 1985-01-31
ES478156A1 (en) 1979-11-01
FI71930C (en) 1987-03-09
FI771763A (en) 1977-12-04
ES489883A0 (en) 1981-02-16
SE8203161L (en) 1982-05-19
CH646426A5 (en) 1984-11-30
ES482010A1 (en) 1980-08-16
JPS52151168A (en) 1977-12-15
HU183046B (en) 1984-04-28
SE7706428L (en) 1977-12-04

Similar Documents

Publication Publication Date Title
SE446336B (en) SET TO MAKE A 1.5-DISUBSTITUTED HYDANTOIN WHICH HAS INHIBITIVE EFFECT ON BLOOD SPOT SEGREGATION
NO143484C (en) STEERABLE, ENGINE WHEELS.
NL7704952A (en) FAULT COMPENSATION SYSTEM.
NL7600178A (en) 1,3,4 SUBSTITUTED PYRAZOLINE DERIVATIVES.
NO144597C (en) ROTATION PRESSURE DRIVER.
IT1103475B (en) INTERFENILEN 8-AZA-9-DIOSSOTIA-11.12-SECOPROSTAGLANDINE
NO803592L (en) 4,5-Saturated PROSTANIC ACID DERIVATIVES.
NL7803720A (en) (1.5) PYRIDO2,3-BBENZOTHIAZEPINE DERIVATIVES.
NO148218C (en) DRIVERLOAD, SPECIAL FOR MOTORCYCLES.
IT1079576B (en) 7,15-DIAZADISPIRO- (5.1.5.3) -EXADECANS 14-REPLACED AS UV STABILIZERS
DK145122C (en) SUBSTITUTED 2,1,3-BENZOTHIADIAZINE COMPOUNDS FOR USE AS HERBICIDES
IT8120863A0 (en) BEARING LOADED BY PERIODIC PRESSURE TIPS.
NO147381C (en) PROCEDURE FOR PREPARING 2,6-DITERATE-BUTYLPHENOL.
NL7706823A (en) PRESSURE FOOT.
NL7713438A (en) PHARMACEUTICALLY ACTIVE 2-PLACE SUBSTITUTED 1- (EPSILON-AMINOALKOXY) BENZENE DERIVATIVES.
SE7513235L (en) WAY TO PRODUCE 1,4-BENZODIOXANES.
NL7801036A (en) AROMACOMPOSITION, AS WELL AS A FOOD, CONTAINING AN ALKYLTHIA SOLE.
SU594587A2 (en) Divider by 3.5
FI783583A (en) BYGGNADSELEMENT I FORM AV ISOLERINGSELEMENT, GOLVELEMENT, M.M.
PT66113B (en) 1,3-DIHYDRO-1'-DIMETHYLPHOSPHINYL ALKYL-3-PHENYLSPIRO / ISOBENZOFURAN / S.
NL7700582A (en) LIQUID INJECTABLE NICLOFOLAN FORMULATIONS.
NL7707551A (en) 2,5-DICHLORO-4-BROMOPHENYLAZO-4-CHLOROPHENYL SULFIDE.
SE418303B (en) SET TO MAKE A POLYCARBAMIDS MORPHET USING 4,17-DIOXAEICOSANDIAMINE-1.20 AS DIAMINO COMPONENT
IT7823795A0 (en) 1,2,4-TRIAZOLIDIN-3-ONI E-TIONI FUNGICIDES.
NO153453C (en) STABILIZED 1,1,1-TRICLORETHANE.